

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-29 (canceled)

30. (New) A method for the diagnosis of tumors, comprising
obtaining a sample from a subject suspected of containing tumor cells,
contacting said sample with an antibody or an antigen-binding fragment
thereof, which is directed against the epitope 52-60 of the urokinase receptor
(uPAR), wherein a reaction of the antibody or the antigen-binding fragment
thereof with tumor cells in the sample is indicative of a tumor and a prognosis of
a malignant disease in said subject.

31. (New) The method according to claim 30, wherein said tumor cells are
disseminated tumor cells in bone marrow.

32. (New) The method according to claim 30, wherein said sample is contacted
with said antibody or an antigen-binding fragment in an ELISA.

33. (New) The method according to claim 30, wherein said reaction of the
antibody or the antigen-binding fragment thereof with tumor cells is determined in
a double-fluorescence detection method.

34. (New) The method according to claim 30, wherein said antibody is the monoclonal antibody IIIF10, fragments thereof, or an antibody or antibody fragment having a binding specificity equivalent to monoclonal antibody IIIF10.

35. (New) The method according to claim 34, wherein said antibody comprises

(a) a CDR3-VH amino acid sequence (I)

D G S M G G F D Y (SEQ ID NO:5), and/or

(b) a CDR3-VL amino acid sequence (II)

L Q H W N Y P Y T (SEQ ID NO:6).

36. (New) A recombinant polypeptide which has antibody properties, comprising

(a) a CDR3-VH amino acid sequence (I)

D G S M G G F D Y (SEQ ID NO:5), and/or

(b) a CDR3-VL amino acid sequence (II)

L Q H W N Y P Y T (SEQ ID NO:6).

37. (New) The recombinant polypeptide according to claim 36, wherein said polypeptide is an scFv antibody fragment.

38. (New) The recombinant polypeptide according to claim 36, wherein said polypeptide is a humanized antibody fragment.

39. (New) The recombinant polypeptide according to claim 36, wherein said polypeptide is coupled to an effector group.